Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children
Status:
Withdrawn
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
IGHN2 is an international, multicenter, double blind, randomized controlled trial aimed at
assessing the efficacy on organ dysfunctions of Intravenous Immunoglobulins (IVIG) treatment
in the acute phase of streptococcal or staphylococcal toxic shock syndrome in children.